[Skip to Navigation]
September 1958

The Uricosuric Action of Bishydroxycoumarin (Dicumarol)

AMA Arch Intern Med. 1958;102(3):389-391. doi:10.1001/archinte.1958.00030010389006

Although the anticoagulant action of bishydroxycoumarin (Dicumarol) has been thoroughly studied, clinically as well as in the laboratory, it is surprising that little attention has been paid to other possible pharmacologic effects of this drug. Some physicians have felt that the drug may have a possible analgetic effect; others believe that treatment with bishydroxycoumarin may increase the speed of resorption of thrombi. Sougin-Mibashan and Horwitz1 have shown that ethyl biscoumacetate (Tromexan), a related coumarin derivative, increases uric acid excretion. Because of a special interest in patients with arteriosclerotic heart disease who exhibit hyperuricemia, we have investigated the effect of bishydroxyxcoumarin on uric acid excretion. The following is a report of the results of an investigation dealing with the effect of therapeutic doses of bishydroxycoumarin on uric acid excretion and uric acid clearance.

Materials and Methods  Eleven patients were studied: five who suffered from myocardial infarction and three, from thromboembolic disease

Add or change institution